What it's actually good for
PQQ (pyrroloquinoline quinone) is a redox-active compound found in trace amounts in kiwi, parsley, natto, and green tea, and produced by soil bacteria. Its pitch rests on one well-documented cell-biology finding: PQQ activates the PGC-1alpha pathway, the same signaling cascade that drives mitochondrial biogenesis — the creation of new mitochondria. That mechanism is real and repeatedly shown in cell and animal work. What's much thinner is evidence that taking 20 mg of PQQ a day meaningfully changes how a human being feels or performs. The human trials that exist are small, several are funded by the ingredient's manufacturer, and what they found is more modest than the marketing suggests.
What the research says
Mitochondrial biogenesis signaling (Grade C, mechanistic). In a 2020 trial of 23 untrained men, 20 mg/day of PQQ for six weeks during an endurance program significantly raised PGC-1alpha protein levels compared to placebo (Hwang et al.) — a real biomarker shift. But it didn't translate into better aerobic performance; both groups improved by similar amounts. That gap between "moved a biomarker" and "changed an outcome" shows up across the PQQ literature.
Cognitive function in older and middle-aged adults (Grade C, small trials). Itoh et al. (2016) gave 41 healthy elderly adults 20 mg/day of BioPQQ for 12 weeks and found smaller declines on the Stroop interference test — a measure of attention and working memory — versus placebo, with no adverse effects. A 2023 Food & Function trial (Tamakoshi et al., funded by Mitsubishi Gas Chemical, BioPQQ's manufacturer) split adults aged 20-65 by age band: those 20-40 improved on cognitive flexibility and processing speed within 8 weeks, while those 41-65 needed the full 12 weeks to show gains in composite and verbal memory. A 2024 trial in 34 elderly adults with mild cognitive impairment paired PQQ with hydrogen-producing magnesium and reported higher serum BDNF, better cerebral oxygenation, and improved mental-orientation scores after six weeks (Baltic et al.) — but because it tested a PQQ-plus-hydrogen combination, the result can't be credited to PQQ alone.
Put together, there's a real and repeated signal that PQQ does something measurable in the brain and in mitochondrial signaling. But every trial runs 23-41 people over 6-12 weeks, and the industry ties on two of them warrant a discount. That's a Grade C evidence base: worth watching, not worth confident claims about "mitochondrial rejuvenation."
How much, and which form
Human trials consistently use 20 mg/day, almost always as the disodium salt — BioPQQ is the most-studied branded form and what most of the trials above actually tested. It's frequently sold alongside CoQ10 on the theory that both target mitochondrial function, though that specific combination hasn't been tested on its own.
Safety & interactions
Across the trials cited here, PQQ was well tolerated at 20 mg/day for up to 12 weeks, with no serious adverse events reported. What's missing is longer-term human safety data — nothing beyond a few months of daily use has been studied. Treat PQQ accordingly: a compound with a plausible mechanism and encouraging pilot data, not one with an established long-term safety record. This is informational, not medical advice — talk to a clinician before starting, especially if pregnant, nursing, on medication, or managing a chronic condition.
How we picked the brand
A PQQ product earns a spot when it uses the disodium salt form actually used in the trials above (or an equivalent branded form like BioPQQ), states the dose clearly at or near the 20 mg studied amount, and passes independent third-party testing.